Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shutdown Deal Avoids Further US FDA Service Cuts, But Damage May Linger

Executive Summary

Employees are no doubt are excited to resume work and may have a dozen or more major NDAs pending, but agency morale may not recover quickly.

You may also be interested in...



Shutdown Prep: US FDA Updates Plan To Furlough More Employees

New FY 2024 plans would retain only 74% of staff, compared to the original, which retained 81%, but still increase the number of workers retained because of user fees.

Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees

However, user fee carryover balances will not last forever and service cuts are inevitable if a shutdown lingers for several weeks.

House FY2024 FDA Appropriation Bill Cuts Funding

Tobacco rules limiting nicotine and banning menthol in cigarettes also would be defunded in the bill.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel